ADXN — Addex Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CH₣6.67m
- CH₣4.41m
- CH₣0.41m
- 14
- 20
- 43
- 12
Annual income statement for Addex Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.88 | 3.15 | 1.44 | 1.62 | 0.41 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 16.1 | 18.7 | 22 | 3.86 | 3.17 |
| Operating Profit | -12.2 | -15.5 | -20.5 | -2.24 | -2.76 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -12.9 | -15.2 | -20.8 | -2.5 | -4.91 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.9 | -15.2 | -20.8 | -2.5 | -4.91 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -12.9 | -15.2 | -20.8 | -10.6 | 7.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.9 | -15.2 | -20.8 | -10.6 | 7.06 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.482 | -0.445 | -0.46 | -0.034 | -0.05 |
| Dividends per Share |